Skip to Content

Varubi IV (rolapitant) Disease Interactions

There are 3 disease interactions with Varubi IV (rolapitant):


Rolapitant (Includes Varubi IV) ↔ hepatic impairment

Severe Potential Hazard, Moderate plausibility. Applies to: Liver Disease

No dosage adjustment is necessary when using rolapitant in patients with mild or moderate hepatic impairment. The use of rolapitant should be avoided in patients with severe hepatic impairment as there are no clinical or pharmacokinetic data available for these patients. Close monitoring is recommended.


Rolapitant (Includes Varubi IV) ↔ lactose intolerance

Moderate Potential Hazard, Moderate plausibility. Applies to: Lactose Intolerance

Rolapitant tablets contain lactose. Care should be exercised when using this agent in patients with rare hereditary problems of galactose intolerance, severe lactase deficiency with a severe degree of intolerance to lactose- containing products, or of glucose-galactose malabsorption.


Rolapitant (Includes Varubi IV) ↔ renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Population pharmacokinetic analyses suggest that no dose adjustment of rolapitant is required in patients with mild or moderate renal impairment. The effect of severe renal impairment on the pharmacokinetics of rolapitant is unknown to determine a dose. This agent has not been studied in patients with end-stage renal disease requiring hemodialysis. Caution is recommended.

Varubi IV (rolapitant) drug interactions

There are 424 drug interactions with Varubi IV (rolapitant)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.